PubMed Health⌕ Search

Biomedical subjects

S Bi

Publications and source records attributed to S Bi.

44 records · Page 3Linked to original sources
PubMed1993

Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia.

Bone marrow and peripheral blood samples from 36 patients with Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) (30 in chronic phase, four in accelerated phase, and two in blastic crisis) were tested with two CD56 monoclonal antibodies (My31 and Eric 1) using the Facscan flow cytometer. Two- and three-color fluorescence experiments indicated that CD13+/CD33+ myeloid cells from 19 out of the 36 patients were positive for CD56 in 12-77% of the cells. In contrast, no CD56 positivity was documented in myeloid cells from bone marrow (BM) of healthy donors. Immunocytochemical staining (APAAP technique) of CML peripheral blood (PB) and BM slides showed that CD56 expression was detectable from the myelocyte stage with the strongest staining in the metamyelocyte stage. Neutrophils were negative both by flow cytometry and APAAP analysis. In individual CML patients, an increasing number of CD56+ cells were recovered with progressively higher density cuts (1.065-1.077 g/ml), supporting the concept that the antigen level tends to increase during myeloid differentiation. Furthermore, 19% of CML patients coexpressed CD56 and CD34 antigens in 10-45% of the CD34+ cells. The myeloid nature of CD56+/CD34+ CML cells has been ascertained by granulocyte-macrophage colony-forming unit (CFU-GM) assays on CD56+ cells sorted on FACS. Furthermore, in six out of eight CML patients in whom we performed a comparative BM and PB analysis, we found that the CD56 expression was brighter and the number of positive cells significantly higher in the peripheral blood myeloid cells as compared to their BM counterpart. In short-term liquid cultures, low doses (50 U/ml) of alpha interferon down-regulated the CD56 expression in CML cells, accompanied by a significant reduction of the Ph positivity. In conclusion, the expression of CD56 on CML myeloid elements seems to represent an aberrant phenomenon which could affect the cell homing mechanisms and, probably, the pattern of tumor cell dissemination. In patients with CD56+ CML, its detection could be further used as a means of monitoring patients undergoing bone marrow transplantation, since its reappearance is associated with early relapse of the disease.

Antibodies, Monoclonal↗
PubMed1993

The abnormal p53 proteins expressed in CML cell lines are non-functional.

Inactivation of the tumor suppressor function of the p53 gene is found in association with 20-40% cases of chronic myeloid leukemia (CML) in blast crisis. A common mechanism of p53 inactivation in CML is by complete deletion of one p53 allele in association with a point mutation which produces a mutant p53 protein on the remaining allele. Whether the mutant p53 protein, which is generally expressed at an elevated level, plays any role in the pathogenesis of blastic transformation or in maintaining the neoplastic proliferation, as it does in some solid tumors, is unknown. By using an antisense oligonucleotide approach, we investigated the cellular function of known abnormal forms of p53 protein, both mutant and truncated, expressed in CML cell lines. We found that the introduction of p53 antisense oligonucleotides can specifically inhibit the translation of the p53 mRNA. However, inhibiting p53 expression had no effect on cell proliferation, cell viability, and colony formation. There was no change in cell doubling time when the cells were maintained in serum-free medium (SFM) in the presence of antisense oligonucleotides compared with cells maintained in SFM alone. We conclude that the mutant or truncated p53 proteins expressed in the blast cells of CML have no growth-promoting effect and are not required for cell survival and proliferation. We further speculate that the loss of the tumor suppressor function of p53 might be the only mechanism by which p53 is involved in the transition from chronic phase to blast crisis.

Base Sequence↗
PubMed1993

Effects of menadione on 1,2-dimethylhydrazine-induced mouse colon adenocarcinoma.

The effects of menadione (Vit K3) administered at 20 or 40 mg.kg-1 ig 3 times a week for both 24 and 28 wk on 1,2-dimethylhydrazine (DMH)-induced mouse colon adenocarcinomas were investigated. At the 24th wk, the number of colon tumors in Vit K3 20 or 40 mg.kg-1 group (0.3 +/- 0.5 and 0.5 +/- 0.8, respectively) was less than that of DMH controls (2.1 +/- 2.5, P < 0.05), but the difference in incidence of colon tumors in these 3 groups was not significant (P > 0.05). After 28 wk, the tumor incidence of both Vit K3 groups (each 8 of 13) was lower than that of DMH controls (13 of 13, P < 0.05); the number of colon tumors of Vit K3 40 mg.kg-1 group (1.3 +/- 1.3, P < 0.05) was decreased, whereas the Vit K3 20 mg.kg-1 group (3.0 +/- 5.1, P > 0.05) was not different from the DMH controls (7.3 +/- 9.3). Determination of the nuclear DNA content of cells from DMH-induced mouse colon mucosa (24 wk) indicated that Vit K3 20 or 40 mg.kg-1 group showed lower DNA content (1.92 +/- 0.12 C and 1.91 +/- 0.10 C, respectively) decreased values of percent-over-3C and -4C and narrow distribution range. Besides, the colon mucosa of DMH-treated mice (28 wk) showed higher superoxide dismutase (SOD) activity (70 +/- 28 U/mg protein, P < 0.05) than the normal controls (30 +/- 20 U/mg protein). Vit K3 40 mg.kg-1 reduced the elevated SOD activity markedly (44 +/- 23 U/mg protein, P < 0.05).

Adenocarcinoma↗
PubMed1992

p53 in chronic myeloid leukemia cell lines.

Four human chronic myeloid leukemia (CML) cell lines, BV173, K562, KCL-22, and KYO-1, were studied for inactivation of human tumor suppressor gene p53. Southern blotting showed allele deletion in KCL-22 and cytogenetic studies showed a chromosome 17 deletion in KYO-1 but no gross structural abnormalities in the other two lines. Northern blotting showed increased amounts of normal size p53 mRNA in BV-173 and KYO-1, trace amounts in KCL-22, and none in K562. Direct sequencing of p53 cDNA revealed a missense point mutation in KYO-1 and a single base pair deletion consistent with a coding frame shift in KCL-22. Both abnormalities in these myeloid cell lines were located in the highly conserved region of p53. Studies with two monoclonal antibodies showed that the three cell lines with p53 mRNA had readily detectable p53 proteins. In KYO-1 and BV173 cells the p53 protein was located mainly in the nuclei but KCL-22 cells had weak staining in the cytoplasm. Our data support the assumption that inactivation of p53 tumor suppressor function in myeloid blast transformation of CML may result from point mutations or deletions that produce mutant proteins.

Base Sequence↗
PubMed1991

Application of two RNA extraction methods prior to amplification of hepatitis E virus nucleic acid by the polymerase chain reaction.

Amplification of the enterically-transmitted non-A, non-B hepatitis virus (HEV) RNA using conventional reverse transcriptase reactions followed by the polymerase chain reaction (PCR) of the cDNA has not been successful. However, after application of two different RNA capture/extraction methods we were able to amplify HEV nucleic acid from clinical samples and specimens from experimentally infected animals. The first procedure, adapted from an immune electron microscopy (IEM) technique, incorporated an immunocapture step with concentration of the virus-antibody complexes by pelleting in a Beckman airfuge. In the second method, glass powder (or size-fractionated silicon dioxide) was used to capture the RNA from its surrounding milieu by adsorption of the nucleic acid to the silicate particles. Since conventional immunoassays for HEV antigen or antibody are not currently available, the use of these RNA extraction methods, coupled with PCR techniques, will be valuable in screening clinical specimens and in further defining the course of disease using animal infectivity studies.

Adsorption↗
PubMed1989

The distribution of beta-adrenergic receptors in guinea pig lungs and their changes in experimental allergic asthma.

In this paper, the distribution of pulmonary beta-adrenergic receptors (beta-receptors) in normal and experimental allergic asthmatic guinea pigs was determined using autoradiographic method. The results showed that the distribution of beta-receptors in the lung sections was widespread. There was a significant decrease of beta-receptor density in several tissue structures of asthmatic guinea pig lungs compared with the controls, a 23.73% decrease in beta-receptor binding sites in bronchiolar smooth muscles and a 18.65% decrease in bronchial smooth muscles; a 23.53%, a 14.23% and a 17.16% decrease in bronchiolar epithelium, in bronchial epithelium and in alveolar epithelium respectively. The results indicated that the beta-receptor decrease in smooth muscles in experimental asthmatic guinea pig lungs might be one of the important factors which made the tension of smooth muscles increase. The relationship between the beta-receptor decrease of other sites and bronchial asthma needs to be studied further.

Animals↗
PubMedDate not supplied

Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.

OBJECTIVE: CYP3A is the major enzyme responsible for metabolism of the calcineurin inhibitors cyclosporine (CsA) and tacrolimus. Our objective was to determine the relationship between genetic polymorphisms of CYP3A5 with respect to interindividual variability in CsA and tacrolimus pharmacokinetics. METHODS: Kidney transplant recipients receiving CsA (n = 137) or tacrolimus (n = 30) were genotyped for CYP3A5*3 and *6 by a PCR/RFLP method. The patients were grouped according to the CYP3A5 genotype. Dose-adjusted trough levels were correlated with the corresponding genotype. RESULTS: At 3, 6, and 12 months, the tacrolimus dose-adjusted trough levels (dose-adjusted C0) showed a statistically significant difference between the group of CYP3A5*3/*3 (n = 19) and the group of CYP3A5*1 allele carriers. The former was higher than the latter. The CsA dose-adjusted C0 and the actual C0 did not display a significant relation (P < .05) between the group of CYP3A5*3/*3 and the group of CYP3A5*1 allele carriers. CONCLUSION: Patients with the CYP3A5*3/*3 genotype require less tacrolimus to reach target concentrations compared to those with the CYP3A5*1 allele.

Base Sequence↗